Search clinical trials for: Ombitasvir/paritaprevir/ritonavir ± dasabuvir

Total 81 results

AbbVie

Completed

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects (ZIRCON)

Chronic Hepatitis C Infection

United States, Belgium, Germany, Puerto Rico, Spain
AbbVie

Completed

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-III)

Compensated Cirrhosis | Chronic Hepatitis C Infection
AbbVie

Completed

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C (CITRINE)

Chronic Hepatitis C

Israel
AbbVie

Completed

The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland (REACH)

Chronic Hepatitis C
AbbVie
IST GmbH, Germany

Completed

Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium

Chronic Hepatitis C, Genotype 1 or 4
AbbVie
Cato Research; IST GmbH, Germany

Completed

Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada (AMBER)

Chronic Hepatitis C
AbbVie

Completed

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C

Chronic Hepatitis C
Parc de Salut Mar

Completed

Impact of Antiviral Therapy on Gastroesophageal Varices.

Cirrhosis | Chronic Hepatitis C
AbbVie

Completed

ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection

Hepatitis C Virus (HCV)
AbbVie

Completed

A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection (Turquoise-IV)

Chronic Hepatitis C Virus (HCV) Infection
Qing XIe
Gilead Sciences; Tigermed Consulting Co., Ltd

Recruiting

Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C (C-DIAMOND)

Hepatitis C, Chronic

China
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

Algeria, Australia, Belgium, Bulgaria, Canada, Denmark, Finland, France, Germany, Greece, Israel, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Spain, Switzerland, Turkey, Austria, Ireland and more
Lisa Barrett
PEI Provincial Correction Centre

Active, not recruiting

Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment

Hepatitis C Virus
Kirby Institute
AbbVie

Completed

Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P (TARGET3D)

Hepatitis C, Acute

United Kingdom, Australia, New Zealand
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-II)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

United States
Valme University Hospital
Hospital General Universitario Elche; Hospital del SAS de Jerez; Clinica Universidad... and other collaborators

Completed

Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions (FPSMON201401)

Chronic Hepatitis C Infection

Spain
University of Florida
Patient-Centered Outcomes Research Institute; Merck Sharp & Dohme LLC; AbbVie

Completed

Study of Oral Treatments for Hepatitis C (PRIORITIZE)

Chronic Hepatitis C

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy (C_ASCENT)

HIV Infections | Hepatitis C

United States, Puerto Rico
Humanity and Health Research Centre
Beijing 302 Hospital; Nanfang Hospital of Southern Medical University

Completed

DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO) (DASCO)

Chronic Hepatitis C Infection | Hepatitis B Reactivation | HBV Coinfection

China
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults

Chronic Hepatitis C Infection
AbbVie

Completed

A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults (GARNET)

Hepatitis C Virus | Hepatitis C Infection
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection (CERTAIN-1)

Hepatitis C Virus | Chronic Hepatitis C Virus
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection

Chronic Hepatitis C Infection
AbbVie

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection (PEARL-IV)

Chronic Hepatitis C Infection
AbbVie

Completed

A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection (TURQUOISE-I)

Hepatitis C Virus Infection | Chronic Hepatitis C | Human Immunodeficiency Virus Infection | Compensated Cirrhosis and Non-cirrhotics
AbbVie

Completed

A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)

Chronic Hepatitis C | Hepatitis C Virus | Compensated Cirrhosis
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis (TURQUOISE-II)

Compensated Cirrhosis | Chronic Hepatitis C Infection
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C (PEARL-II)

Chronic Hepatitis C Infection
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection (PEARL-III)

Chronic Hepatitis C Infection
Kaiser Permanente
AbbVie

Completed

Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO

Hepatitis C, Chronic

United States
AbbVie

Completed

A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs (HCV PMS)

Hepatitis C Virus (HCV)

Korea, Republic of
Assiut University
Sohag University; South Valley University

Completed

Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease

End-stage Renal Disease | HCV Coinfection

Egypt
AbbVie

Completed

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection (GEODE II)

Hepatitis C Virus (HCV)
AbbVie

Completed

Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®) (HEMATITE)

Chronic Hepatitis C Virus (HCV)

Switzerland
AbbVie

Completed

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C) (LIFE-C)

Chronic Hepatitis C
AbbVie

Completed

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Colombia (outCome)

Chronic Hepatitis C

Colombia
Ottawa Hospital Research Institute
AbbVie

Completed

Pilot HCV Direct Acting Antiviral Therapy and Metabolism (3D)

Hepatitis C

Canada
HaEmek Medical Center, Israel
AbbVie

Completed

Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B

HCV Coinfection

Israel
National Taiwan University Hospital

Completed

eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs

Hepatitis C | Viral Hepatitis C | Renal Disease

Taiwan
Kaiser Permanente
Patient-Centered Outcomes Research Institute; OneFlorida Clinical Research...

Completed

An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C

Hepatitis C, Chronic
AbbVie
IST GmbH, Germany

Completed

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary (VERITAS)

Chronic Hepatitis C
AbbVie

Completed

The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France (OPALE)

Chronic Hepatitis C

France
Kirby Institute

Completed

A Phase IV Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus Infection (D3FEAT)

Hepatitis C, Chronic

Australia
AbbVie

Completed

Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL) (REAL)

Chronic Hepatitis C
AbbVie

Completed

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C (3DUTCH)

Chronic Hepatitis C

Netherlands
Assiut University
Sohag University; South Valley University

Completed

Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure

HCV Coinfection

Egypt
AbbVie

Completed

Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation (CITRIN)

Chronic Hepatitis C

Russian Federation
AbbVie
IST GmbH, Germany

Completed

Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Romania

Chronic Hepatitis C
AbbVie

Completed

Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study

Chronic Hepatitis C
AbbVie

Completed

Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation (HCV RWE)

Chronic Hepatitis C | Genotype 1

3

Subscribe